

OVERVIEW

GenTraceDx is a next-generation precision oncology platform that combines multiomic profiling with continuously updating clinical intelligence.

It transforms cancer diagnostics from a one-time genomic report into an evolving clinical resource that updates as new therapies, biomarkers, and clinical evidence emerge.

THE PROBLEM

Current genomic testing is limited in scope and static in design.

Most tests:

- Rely on fixed gene panels
- Exclude transcriptome-level biology
- Provide a single report at a single point in time

As a result, many patients receive limited actionable insights, and new opportunities that emerge later are often missed.

THE SOLUTION

GenTraceDx introduces a continuously updating model for precision oncology.

The platform:

- Analyzes tumour-normal whole exome and RNA data
- Continuously integrates new clinical evidence
- Updates patient-specific insights over time

When new therapies or clinical trials become relevant, physicians and patients are notified.

PLATFORM COMPONENTS

- Tumour-normal whole exome sequencing (WES)
- Whole-transcriptome RNA analysis
- AI-driven longitudinal interpretation system
- Physician and patient portals for ongoing updates

KEY DIFFERENTIATORS

- **Multiomic depth**
Broader and deeper molecular profiling than panel-based tests
- **Continuous updates**
Insights evolve as new evidence becomes available
- **Clinical integration**
Designed for real-world oncology workflows
- **Scalable deployment**
Built for national and international use

DEVELOPMENT & COLLABORATION

GenTraceDx is being developed through collaboration between:

- **Genetrack Biolabs**
A 30-year leader in regulated diagnostics, medical device manufacturing, and large-scale clinical testing infrastructure
- **Michael Smith Genome Sciences Centre (GSC)**
A globally recognized leader in cancer genomics and clinical sequencing

The project is supported through national genomics funding initiatives, including the Genomic Applications Partnership Program (GAPP).

NATIONAL PILOT

A 500-patient national pilot across Canada will evaluate:

- Clinical utility
- Physician adoption
- Real-world performance

This program will support broader clinical deployment.

MARKET OPPORTUNITY

The global precision oncology market is projected to exceed USD \$300 billion by 2030.

GenTraceDx addresses key limitations of current approaches by combining comprehensive molecular profiling with continuously updating clinical intelligence.

VISION

GenTraceDx establishes a new model for precision oncology, one in which clinical insights are continuously updated, ensuring patients and physicians remain connected to the most current treatment opportunities.